Journal of hypertension

publication venue for

Maintenance of blood pressure by reactive increases in plasma renin activity during salt depletion and renin-angiotensin system inhibition.. 43. 2025
Hypothesis: Reactive increases in plasma renin activity attenuate the fall in blood pressure caused by salt depletion and renin-angiotensin system inhibition.. 43. 2025
Hypertension severity, apparent treatment resistant hypertension and hyperuricemia in the REasons for Geographic And Racial Differences in Stroke (REGARDS) study.. 41. 2023
Quadratic relationship between systolic blood pressure and white matter lesions in individuals with hypertension.. 41. 2022
Comparison of the association of masked hypertension defined by the 2017 ACC/AHA BP guideline versus the JNC7 guideline with left ventricular hypertrophy.. 40. 2022
The association of actigraphy-assessed sleep duration with sleep blood pressure, nocturnal hypertension, and nondipping blood pressure: the coronary artery risk development in young adults (CARDIA) study.. 39. 2021
The association of SBP with mortality in patients with stage 1-4 chronic kidney disease.. 39. 2021
Office, central and ambulatory blood pressure for predicting incident atrial fibrillation in older adults.. 39. 2021
Associations of awake and asleep blood pressure and blood pressure dipping with abnormalities of cardiac structure: the Coronary Artery Risk Development in Young Adults study.. 38. 2020
Sex differences in masked hypertension: the Coronary Artery Risk Development in Young Adults study.. 37. 2019
Hypertension prevalence and risk factors among residents of four slum communities: population-representative findings from Port-au-Prince, Haiti.. 37. 2019
Effect of antihypertensive therapy on development of incident conduction system disease in hypertensive patients.. 37. 2019
Blood pressure and mortality in a prospective cohort of HIV-infected adults in Port-au-Prince, Haiti.. 36. 2018
The relationship of all-cause mortality to average on-treatment systolic blood pressure is significantly related to baseline systolic blood pressure: implications for interpretation of the Systolic Blood Pressure Intervention Trial study.. 36. 2018
Achieving target SBP for lowering the risk of major adverse cardiovascular events in persons with diabetes mellitus.. 36. 2018
Red meat consumption and cardiovascular target organ damage (from the Strong Heart Study).. 35. 2017
Electrocardiographic left atrial abnormalities and risk of incident stroke in hypertensive patients with electrocardiographic left ventricular hypertrophy.. 34. 2016
Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy.. 33. 2015
Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation.. 33. 2015
Relationship of left ventricular systolic function to persistence or development of electrocardiographic left ventricular hypertrophy in hypertensive patients: implications for the development of new heart failure.. 32. 2014
Five-year weight changes associate with blood pressure alterations independent of changes in serum insulin.. 32. 2014
Overweight, adipocytokines and hypertension: a prospective population-based study.. 32. 2014
Psoriasis is associated with subsequent atrial fibrillation in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint study.. 32. 2014
Geometry-independent inclusion of basal myocardium yields improved cardiac magnetic resonance agreement with echocardiography and necropsy quantified left-ventricular mass.. 31. 2013
Systolic left ventricular function according to left ventricular concentricity and dilatation in hypertensive patients: the Losartan Intervention For Endpoint reduction in hypertension study.. 31. 2013
Hypertension-related diseases as a common cause of hospital mortality in Tanzania: a 3-year prospective study.. 31. 2013
Thresholds for pulse wave velocity, urine albumin creatinine ratio and left ventricular mass index using SCORE, Framingham and ESH/ESC risk charts.. 30. 2012
Heritability of central blood pressure and arterial stiffness: a twin study.. 30. 2012
Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.. 30. 2012
Impact of lower achieved blood pressure on outcomes in hypertensive patients.. 30. 2012
Can ambulatory blood pressure measurements substitute assessment of subclinical cardiovascular damage?. 30. 2012
Effects of diabetes and hypertension on structure and distensibilty of human small coronary arteries.. 30. 2012
In-treatment stroke volume predicts cardiovascular risk in hypertension.. 29. 2011
Sex differences in obesity-related changes in left ventricular morphology: the Strong Heart Study.. 29. 2011
Changes in subclinical organ damage vs. in Framingham risk score for assessing cardiovascular risk reduction during continued antihypertensive treatment: a LIFE substudy.. 29. 2011
Initial left-ventricular mass predicts probability of uncontrolled blood pressure in arterial hypertension.. 29. 2011
Performance of electrocardiographic criteria for left ventricular hypertrophy as compared with cardiac computed tomography: from the Rule Out Myocardial Infarction Using Computer Assisted Tomography trial.. 28. 2010
In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the Losartan Intervention For Endpoint reduction study.. 28. 2010
Relationship of left atrial enlargement to persistence or development of ECG left ventricular hypertrophy in hypertensive patients: implications for the development of new atrial fibrillation.. 28. 2010
Are coronary revascularization and myocardial infarction a homogeneous combined endpoint in hypertension trials? The Losartan Intervention For Endpoint reduction in hypertension study.. 28. 2010
Diabetes and incident heart failure in hypertensive and normotensive participants of the Strong Heart Study.. 28. 2010
Impact of hypertension on left ventricular structure in patients with asymptomatic aortic valve stenosis (a SEAS substudy).. 28. 2010
Relations of central and brachial blood pressure to left ventricular hypertrophy and geometry: the Strong Heart Study.. 28. 2010
Human dopamine beta-hydroxylase (DBH) regulatory polymorphism that influences enzymatic activity, autonomic function, and blood pressure.. 28. 2010
Relation of left ventricular mass and concentric remodeling to extent of coronary artery disease by computed tomography in patients without left ventricular hypertrophy: ROMICAT study.. 27. 2009
Risk stratification with the risk chart from the European Society of Hypertension compared with SCORE in the general population.. 27. 2009
Effect of peroxisome proliferator-activated receptor-alpha siRNA on hypertension and renal injury in the rat following nitric oxide withdrawal and high salt diet.. 27. 2009
Incidence of heart failure in relation to QRS duration during antihypertensive therapy: the LIFE study.. 27. 2009
Novel genetic variants contributing to left ventricular hypertrophy: the HyperGEN study.. 27. 2009
Which markers of subclinical organ damage to measure in individuals with high normal blood pressure?. 27. 2009
Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study.. 27. 2009
Left ventricular mass and incident hypertension in individuals with initial optimal blood pressure: the Strong Heart Study.. 26. 2008
Effects of papillary muscles and trabeculae on left ventricular quantification: increased impact of methodological variability in patients with left ventricular hypertrophy.. 26. 2008
Factor relationships of metabolic syndrome and echocardiographic phenotypes in the HyperGEN study.. 26. 2008
Left atrial systolic force in hypertensive patients with left ventricular hypertrophy: the LIFE study.. 26. 2008
Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study.. 26. 2008
Clinical impact of 'in-treatment' wall motion abnormalities in hypertensive patients with left ventricular hypertrophy: the LIFE study.. 26. 2008
Thiazide diuretics, endothelial function, and vascular oxidative stress.. 26. 2008
Cardiovascular risk prediction by N-terminal pro brain natriuretic peptide and high sensitivity C-reactive protein is affected by age and sex.. 26. 2008
World Health Organization (WHO) and International Society of Hypertension (ISH) risk prediction charts: assessment of cardiovascular risk for prevention and control of cardiovascular disease in low and middle-income countries.. 25. 2007
Assessment of the interaction of heritability of volume load and left ventricular mass: the HyperGEN offspring study.. 25. 2007
Electrocardiographic characteristics and metabolic risk factors associated with inappropriately high left ventricular mass in patients with electrocardiographic left ventricular hypertrophy: the LIFE Study.. 25. 2007
Presidential Address: 21st Scientific Meeting of the International Society of Hypertension: dietary sodium and cardiovascular disease: the 'J'-shaped relation.. 25. 2007
Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies.. 25. 2007
Electrocardiographic strain pattern and left ventricular diastolic function in hypertensive patients with left ventricular hypertrophy: the LIFE study.. 24. 2006
N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy.. 24. 2006
Blood pressure normalization is associated with normal left ventricular mass but not carotid geometry: the ICARe Dicomano Study.. 24. 2006
High-sensitivity C-reactive protein is only weakly related to cardiovascular damage after adjustment for traditional cardiovascular risk factors.. 24. 2006
Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study.. 24. 2006
Renal dysfunction and ischemic heart disease mortality in a hypertensive population.. 23. 2005
Vascular but not cardiac remodeling is associated with superoxide production in angiotensin II hypertension.. 23. 2005
Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy.. 23. 2005
Aortic valve sclerosis is associated with preclinical cardiovascular disease in hypertensive adults: the Hypertension Genetic Epidemiology Network study.. 23. 2005
Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy.. 23. 2005
Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.. 22. 2004
N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study.. 22. 2004
Heritability of left ventricular dimensions and mass in American Indians: The Strong Heart Study.. 22. 2004
Influence of fat-free mass on detection of appropriateness of left ventricular mass: the HyperGEN Study.. 21. 2003
Nitric oxide inhibition as a mechanism for blood pressure increase during salt loading in normotensive postmenopausal women.. 21. 2003
Pulse pressure/stroke index and left ventricular geometry and function: the LIFE Study.. 21. 2003
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.. 20. 2002
Change in cardiovascular risk profile by echocardiography in low- or medium-risk hypertension.. 20. 2002
Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study.. 20. 2002
Impact of diastolic Doppler indices on exercise capacity in hypertensive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy).. 20. 2002
Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study.. 20. 2002
Association of left ventricular hypertrophy with metabolic risk factors: the HyperGEN study.. 20. 2002
Relation of QT interval and QT dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients. The LIFE study. The Losartan Intervention For Endpoint Reduction.. 19. 2001
High and low serum potassium associated with cardiovascular events in diuretic-treated patients.. 19. 2001
Cigarette smoke-induced endothelium dysfunction: role of superoxide anion.. 19. 2001
Prognostic implications of the compensatory nature of left ventricular mass in arterial hypertension.. 19. 2001
Relation of left ventricular geometry and function to systemic hemodynamics in hypertension: the LIFE Study. Losartan Intervention For Endpoint Reduction in Hypertension Study.. 19. 2001
Left ventricular wall stresses and wall stress-mass-heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint reduction in hypertension.. 18. 2000
The L10F mutation of angiotensinogen is rare in pre-eclampsia.. 18. 2000
Relative influence of insulin resistance versus blood pressure on vascular changes in longstanding hypertension. ICARUS, a LIFE sub study. Insulin Carotids US Scandinavia.. 18. 2000
Impact of arterial elastance as a measure of vascular load on left ventricular geometry in hypertension.. 17. 1999
Left ventricular chamber and wall mechanics in the presence of concentric geometry.. 17. 1999
Parathyroid hormone-related protein expression in vascular smooth muscle of spontaneously hypertensive rats: evidence for lack of response to angiotensin II.. 16. 1998
Clinical impact of various geometric models for calculation of echocardiographic left ventricular mass.. 16. 1998
Distribution and determinants of cardiovascular events during 20 years of successful antihypertensive treatment.. 16. 1998
Is the absence of a normal nocturnal fall in blood pressure (nondipping) associated with cardiovascular target organ damage?. 15. 1997
Relation of left ventricular longitudinal and circumferential shortening to ejection fraction in the presence or in the absence of mild hypertension.. 15. 1997
Effect of high-performance liquid chromatography on plasma angiotensin II measurements in treated and untreated normotensive and hypertensive patients.. 15. 1997
Altered cellular calcium responsiveness to insulin in normal and hypertensive pregnancy.. 14. 1996
Characterization of ouabain-like immunoreactivity in human urine.. 14. 1996
Ageing induces left ventricular concentric remodelling in normotensive subjects.. 13. 1995
Midwall left ventricular performance in salt-loaded Dahl rats: effect of AT1 angiotensin II inhibition.. 13. 1995
Angina pectoris by Rose questionnaire does not predict cardiovascular disease in treated hypertensive patients.. 13. 1995
Relationship of effective arterial elastance to demographic and arterial characteristics in normotensive and hypertensive adults.. 13. 1995
Measures of blood pressure and myocardial infarction in treated hypertensive patients.. 13. 1995
Response to the captopril test is dependent on baseline renin profile.. 12. 1994
Ethnicity and the relationship of sodium intake to blood pressure.. 12. 1994
Comparison of classification of the severity of hypertension by blood pressure level and by World Health Organization criteria in the prediction of concurrent cardiac abnormalities and subsequent complications in essential hypertension.. 11. 1993
Control of blood pressure and end-organ damage in maturing salt-loaded stroke-prone spontaneously hypertensive rats by oral angiotensin II receptor blockade.. 11. 1993
In vivo left ventricular anatomy in rats with two-kidney, one clip and one-kidney, one clip renovascular hypertension.. 10. 1992
Pressor actions of arginine vasopressin in pithed Sprague-Dawley, Wistar-Kyoto and spontaneously hypertensive rats before and after treatment with nifedipine or pertussis toxin.. 9. 1991
A new circulating hypertensive factor in the plasma of essential hypertensive subjects.. 8. 1990
Subcellular membrane properties in vascular and non-vascular smooth muscles of Dahl hypertensive rats.. 4. 1986
Cardiac regression and blood pressure control in the Dahl rat treated with either enalapril maleate (MK 421, an angiotensin converting enzyme inhibitor) or hydrochlorothiazide.. 1. 1983
Prorenin cryoactivation as a possible cause of normal renin levels in patients with primary aldosteronism.. 23. 2005
Reply. 2021
Prediabetes: an unexplored cardiovascular disease risk factor. 2021
Salt sensitivity: state of the science. 2017
Reply. 2019
Association of central and peripheral pulse pressure with intermediate cardiovascular phenotypes. 2012
Comparison of the SCOPE and LIFE results. 2003
Effects of changes in body position on 24 h ambulatory blood pressure. 2001
Global challenge for overcoming high blood pressure: Fukuoka Statement, 19 October 2006. 2007
Does nondipping blood pressure provide prognostic information for all-cause and cardiovascular mortality independent of nighttime blood pressure?. 42. 2024
An age-old test in old age: ECG left ventricular hypertrophy and cardiovascular outcomes in the elderly.. 34. 2016
Does electrocardiography still have a place in hypertension?. 34. 2016
First-degree atrioventricular block may not be that benign after all.. 32. 2014
Regression of target organ damage.. 31. 2013
Prediction and prevention of atrial fibrillation in patients with high blood pressure or history of hypertension.. 30. 2012
Impaired left ventricular systolic function in patients with left ventricular hypertrophy.. 29. 2011
Should regression or prevention of development of the electrocardiographic strain pattern be an indication for more aggressive treatment in hypertensive patients?. 28. 2010
Blood-pressure-related disease is a global health priority.. 26. 2008
Does blood pressure control require a Cuban-style revolution?. 24. 2006
Quality of life in hypertensive patients: does it matter and should we measure it?. 23. 2005
Hypertension, silver bullets and faded dreams.. 22. 2004
Blood pressure measures, relative and absolute risk, and international differences.. 20. 2002
Measurement of left ventricular mass: methodology and expertise.. 15. 1997
Is there a role for non-invasive screening tests in diagnosing renal artery stenosis?. 14. 1996
Echocardiography in arterial hypertension: when, why and how?. 12. 1994
On the renal basis for essential hypertension: nephron heterogeneity with discordant renin secretion and sodium excretion causing a hypertensive vasoconstriction-volume relationship. 1988
Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. 2014

VIVO Weill Cornell Medical College

Journal of hypertension Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)